The assessment of bleeding and ischemic risk is a crucial step in establishing appropriate
composition and duration of dual antiplatelet therapy (DAPT) in patients with acute coronary …

Because guidelines and recommendations in response to multiple randomized clinical trials
(RCTs) of new therapies undergo rapid changes, antithrombotic therapies for patients after …

Aims The relative safety and efficacy of de-escalation, extended duration (ED)(> 12-months),
and standard dual antiplatelet therapy for 12-months (DAPT-12) in patients with coronary …

Stable coronary artery disease (CAD) has recently been replaced by a new entity described
as chronic coronary syndrome (CCS). This new entity has been developed based on a …

Oral P2Y12 inhibitors are commonly prescribed for cardiovascular disease and include
clopidogrel, prasugrel, and ticagrelor. Each of these drugs has its strengths and …

Single antiplatelet therapy represents the cornerstone of thrombosis prevention in
atherosclerotic cardiovascular disease. Dual antiplatelet therapy (DAPT), consisting of …

Introduction Non-ST-segment elevation acute coronary syndromes (NSTE-ACS), including
non-ST-segment-elevation myocardial infarction (NSTEMI) and unstable angina, represent a …

There is considerable interindividual variability in the response to antiplatelet and
anticoagulant therapies, and this variation may be attributable to genetic variants. There has …

The origins of pharmacogenetics date back to the 1950s, when it was established that inter-
individual differences in drug response are partially determined by genetic factors. Since …

The Age, Body mass index, Chronic kidney disease, Diabetes mellitus, and CYP2C19
GENEtic variants (ABCD‐GENE) score was developed to identify patients at risk for …